Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder following Alzheimer’s disease. By the time motor symptoms manifest, a significant proportion of nigrostriatal neurons …
Background: Glioblastoma (GBM) is the most common and the most aggressive primary malignant tumor in the adult brain. Patient survival remains poor despite treatment with …
Glioblastoma (GBM) is a Grade IV malignancy originating from glial progenitor cells and comprises about half of all primary malignant brain tumors. GBM has a …
Among aneurysmal subarachnoid hemorrhage (aSAH) patients, delayed cerebral ischemia (DCI) resulting from cerebral vasospasm is a common complication impacting treatment and outcomes. Patients with asymptomatic …
Traumatic brain injury (TBI) is a well-established risk factor for Parkinson’s disease (PD), though it remains unclear how TBI impacts the time course and progression …
Background: Andexanet alfa was recently approved as a reversal agent for the Factor Xa inhibitors (FXai) apixaban and rivaroxaban, but its impact on long-term outcomes …